MedPath

BRISTOL MYERS SQUIBB

🇺🇸United States
Ownership
-
Established
1989-01-01
Employees
30K
Market Cap
$97.5B
Website
https://www.bms.com/

Effect of BMS-914392 on Pharmacokinetics of Metoprolol

Phase 1
Completed
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2010-09-30
Last Posted Date
2011-02-02
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
18
Registration Number
NCT01211821
Locations
🇺🇸

Pra International, Lenexa, Kansas, United States

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

Phase 2
Completed
Conditions
Hepatitis B Virus
Interventions
Drug: pegIFNα-2a
Drug: PegIFN lambda
Drug: pegIFN
First Posted Date
2010-09-17
Last Posted Date
2015-10-09
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
197
Registration Number
NCT01204762
Locations
🇺🇸

Sc Clinical Research, Inc., Garden Grove, California, United States

🇺🇸

Mercy Medical Center, Baltimore, Maryland, United States

🇺🇸

Office Of Sing Chan Md, Flushing, New York, United States

and more 14 locations

Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter

Phase 1
Terminated
Conditions
Venous Thromboembolism
Interventions
First Posted Date
2010-09-06
Last Posted Date
2017-04-07
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
13
Registration Number
NCT01195727
Locations
🇺🇸

The Toledo Children'S Hospital, Toledo, Ohio, United States

🇺🇸

Penn State Hershey Children'S Hospital, Hershey, Pennsylvania, United States

🇺🇸

Children'S Hospital Of Orange County, Orange, California, United States

and more 2 locations

Ph IIA Study (SOC +/- NS5B)

Phase 2
Completed
Conditions
Hepatitis C Virus
Interventions
First Posted Date
2010-09-01
Last Posted Date
2015-10-09
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
39
Registration Number
NCT01193361
Locations
🇺🇸

Options Health Research, Llc, Tulsa, Oklahoma, United States

🇺🇸

Advanced Clinical Research Institute, Anaheim, California, United States

🇺🇸

Loyola University Medical Center, Maywood, Illinois, United States

and more 7 locations

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

Completed
Conditions
Leukemia, Myeloid, Chronic-Phase (CML-CP)
Interventions
First Posted Date
2010-08-25
Last Posted Date
2016-09-30
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
173
Registration Number
NCT01188278

Methotrexate - Inadequate Response Device Sub-Study

Phase 3
Completed
Conditions
Rheumatoid Arthritis (RA)
Interventions
Device: Abatacept combination product (ACP)
First Posted Date
2010-07-30
Last Posted Date
2012-01-12
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
62
Registration Number
NCT01173120

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

Phase 2
Completed
Conditions
Hepatitis C Virus
Interventions
First Posted Date
2010-07-28
Last Posted Date
2015-10-12
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
512
Registration Number
NCT01170962
Locations
🇺🇸

Scripps Clinic, La Jolla, California, United States

🇺🇸

Alabama Liver & Digestive Specialists (Alds), Montgomery, Alabama, United States

🇺🇸

Liver Associates Of Texas, Houston, Texas, United States

and more 34 locations

Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

Phase 2
Completed
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
First Posted Date
2010-07-22
Last Posted Date
2015-10-12
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
11
Registration Number
NCT01167244
Locations
🇯🇵

Local Institution, Koto-Ku, Tokyo, Japan

Observational Real-world Evaluation of Cost of Infections of Rheumatoid Arthritis (RA) Patients on Biologics

Completed
Conditions
Rheumatoid Arthritis
First Posted Date
2010-07-21
Last Posted Date
2012-04-13
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
4000
Registration Number
NCT01166620

Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer

Phase 1
Completed
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: Ipilimumab, 3 mg
Drug: Ipilimumab, 10 mg
First Posted Date
2010-07-19
Last Posted Date
2014-07-22
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
15
Registration Number
NCT01165216
Locations
🇯🇵

Local Institution, Chuo-ku, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath